2019 Assessment

The Institute for Clinical and Economic Review (ICER) has published its first annual report on Unsupported Price Increases (UPI) of prescription drugs in the United States. The agency has identified the costliest price hikes in the U.S. that are not supported by new clinical evidence. 

ICER began its analysis by ranking the top 100 drugs by sales revenue in the US. The list was filtered to 77 treatments that experienced Wholesale Acquisition Cost (WAC) increases at rates of more than twice the medical Consumer Price Index (CPI) across 2017 and 2018. ICER then narrowed the list to the top ten treatments that had estimated net price increases responsible for the largest increases in US spending over those two years. The study finally identified nice drugs whose price increases have contributed to the largest net increase in drug spending in the US. Seven of these products had no new important evidence to support their price increases.

The combined price hikes from the evaluated seven drugs, in 2017 and 2018, contributed to a $5.1 billion increase in spending.

AbbVie’s Humira was identified as top-of-the-list when it comes to costly price increases that are not supported by new clinical evidence. The rheumatoid arthritis drug accounted for the biggest increase in drug spending in the U.S. ($1.8 billion) with a 15.9 percent net price increase over the period.